Abstract
Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a patient with MS treated with ocrelizumab. The intervals between ocrelizumab infusions and vaccination were as recommended by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. A reactive immune response was observed in this patient following vaccination. This suggests that appropriate intervals between ocrelizumab infusions and COVID-19 vaccinations may permit the generation of efficacious immune responses in patients receiving B-lymphocyte depleting therapies.
Keywords: Multiple sclerosis; anti-CD20 therapy; coronavirus disease 2019; ocrelizumab; severe acute respiratory syndrome coronavirus-2; vaccine.
【저자키워드】 Coronavirus disease 2019, Vaccine, multiple sclerosis, severe acute respiratory syndrome coronavirus-2, anti-CD20 therapy, Ocrelizumab, 【초록키워드】 COVID-19, coronavirus disease, Vaccine, immune response, vaccination, therapy, COVID-19 vaccination, Patient, Neuroimmunology, Therapies, anti-CD20, Society, acute respiratory syndrome, Multiple, sclerosis, Section, reactive, abnormal immune response, evaluated, receiving, treated, suggested, depleting, interval, receive, 【제목키워드】 vaccination, Antibody Response, Case report, Patient, Pfizer-BioNTech, Coronavirus-2, acute respiratory syndrome, treated,